Jasper Therapeutics Inc. JSPR

$10.75 -0.77 (-6.68%)

Valuation

Market cap
12,764,000
Revenue TTM
$0
Net income TTM
$-75,800,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
10,900
Avg volume
18,548
Day's range
$10.61 – $11.50
Shares out
1,108,000
Stochastic %K
19%
Beta
3.30
Analysts
Moderate Buy
Price target
$89.83

Price

Company profile

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditionin...

Show more

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650-549-1400
Website
https://jaspertx.com
Address
2200 Bridge Pkwy, Suite #102, Redwood City, United States

Latest news

No headlines yet.